Oruka Therapeutics (ORKA) Preferred Stock Liabilities (2024)

Oruka Therapeutics (ORKA) posted quarterly Preferred Stock Liabilities of $52.8 million for Q3 2024.

Oruka Therapeutics (ORKA) Preferred Stock Liabilities (2024) Analysis & Trends

Oruka Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $52.8 million for Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Oruka Therapeutics 6.98 Bn 5.25 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2024 52.84 Mn